Overview

A Study of AL2846 on Tolerance and Pharmacokinetics

Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
A study of AL2846,a C-met/Hepatocyte growth factor tyrosine kinase inhibitor,in patients with advanced cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd